A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma

PI3K and cancer: lessons, challenges and opportunities

Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,716 · see citing works

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,614 · see citing works

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Long, G. V., Stroyakovskiy, D., Gogas, H. J., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60898-4 · Cited by 1,397 · see citing works

BrafV600E cooperates with Pten loss to induce metastatic melanoma

Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189 · see citing works

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Bendell, J. C., Rodon, J. A., Burris, H. A., de Jonge, M. J. A., Verweij, J., Birle, D. C., Demanse, D., Buck, S. S. D., Ru, Q. C., Peters, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 687 · see citing works

Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma

Goel, V., Lazar, A. J., Warneke, C. L., Redston, M. S., & Haluska, F. G. (2005) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700026 · Cited by 389 · see citing works

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

Bedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste, J., Van Cutsem, E., Pérez-García, J., Stathis, A., Britten, C. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1814 · Cited by 324 · see citing works

Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

Nathanson, K. L., Martin, A., Wubbenhorst, B. S., Greshock, J. D., Letrero, R., D'Andrea, K. P., O'Day, S. J., Infante, J. R., Falchook, G. S., Arkenau, H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0827 · Cited by 195 · see citing works

Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma

Kwong, L. N., & Davies, M. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0142 · Cited by 103 · see citing works

Dual MAPK / PI3K pathway inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS mutant and wild type melanoma

Algazi, A., Esteve-Puig, R., Nosrati, A., Hinds, B., Hobbs‐Muthukumar, A., Nandoskar, P., Ortiz-Urda, S., Chapman, P., & Daud, A. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12644 · Cited by 59 · see citing works

A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma

Grippo, J. F., Zhang, W., Heinzmann, D., Yang, K., Wong, J., Joe, A. K., Münster, P. N., Sarapa, N., & DAUD, A. I. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2324-5 · Cited by 48 · see citing works

Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation–positive metastatic melanoma patients (pts).

McArthur, G. A., Ribas, A., Chapman, P. B., Flaherty, K. T., Kim, K. B., Puzanov, I. J., Nathanson, K. L., Lee, R. J., Koehler, A., Spleiss, O., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.8502 · Cited by 40 · see citing works

RAS-targeted therapies: is the undruggable drugged?

Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

Mishra, R., Patel, H. M., Alanazi, S., Kilroy, M. K., & Garrett, J. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073464 · Cited by 292 · see citing works

Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy

Sirico, M., D’Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023) · Cancers · doi:10.3390/cancers15030703 · Cited by 121 · see citing works

BRAF Gene and Melanoma: Back to the Future

Ottaviano, M., Giunta, E. F., Tortora, M., Curvietto, M., Attademo, L., Bosso, D., Cardalesi, C., Rosanova, M., Placido, P. D., Pietroluongo, E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073474 · Cited by 120 · see citing works

Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer

Zhang, Z., Richmond, A. J., & Yan, C. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137353 · Cited by 105 · see citing works

Melanoma Brain Metastases in the Era of Target Therapies: An Overview

Becco, P., Gallo, S., Poletto, S., Frascione, M. P. M., Crotto, L., Zaccagna, A., Paruzzo, L., Caravelli, D., Carnevale‐Schianca, F., & Aglietta, M. (2020) · Cancers · doi:10.3390/cancers12061640 · Cited by 48 · see citing works

PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches

Caforio, M., de Billy, E., Angelis, B. D., Iacovelli, S., Quintarelli, C., Paganelli, V., & Folgiero, V. (2021) · Cancers · doi:10.3390/cancers13164040 · Cited by 40 · see citing works

The future of targeted kinase inhibitors in melanoma

Caksa, S., Baqai, U., & Aplin, A. E. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108200 · Cited by 33 · see citing works

Targeting RAS in neuroblastoma: Is it possible?

Lin, L., Miao, L., Lin, H., Cheng, J., Li, M., Zhuo, Z., & He, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108054 · Cited by 24 · see citing works

Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells

Hoefsmit, E. P., van Royen, P. T., Rao, D., Stunnenberg, J. A., Dimitriadis, P., Lieftink, C., Morris, B., Rozeman, E. A., Reijers, I. L. M., Lacroix, R., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0494 · Cited by 22 · see citing works

RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted Therapy

Jebali, A., Battistella, M., Lebbé, C., & Dumaz, N. (2021) · Biomedicines · doi:10.3390/biomedicines9101498 · Cited by 14 · see citing works

Melanoma Brain Metastases: Review of Histopathological Features and Immune-Molecular Aspects

Salvati, L., Mandalà, M., & Massi, D. (2020) · Melanoma Management · doi:10.2217/mmt-2019-0021 · Cited by 14 · see citing works

A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF ‐mutated cancers

Algazi, A. P., Moon, J., Lao, C. D., Chmielowski, B., Kendra, K. L., Lewis, K. D., Gonzalez, R. C., Kim, K., Godwin, J. E., Curti, B. D., et al. (2024) · Cancer · doi:10.1002/cncr.35200 · Cited by 13 · see citing works

A Long Way to Go: A Scenario for Clinical Trials of PI3K Inhibitors in Treating Cancer

Trigueiros, B. A. F. D. S., Santos, I. J. S., Pimenta, F. P., & Ávila, A. R. (2024) · Cancer Control · doi:10.1177/10732748241238047 · Cited by 13 · see citing works

Protein Signatures of NK Cell–Mediated Melanoma Killing Predict Response to Immunotherapies

Cappello, S., Sung, H., Ickes, C., Gibhardt, C. S., Vultur, A., Bhat, H., Hu, Z., Brafford, P. A., Denger, A., Stejerean‐Todoran, I., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0164 · Cited by 13 · see citing works

Double-sided niche regulation in skin stem cell and cancer: mechanisms and clinical applications

Pham, Q. T. T., Kuo, Y., Chang, W., Weng, H.-J., & Huang, Y.-H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02289-8 · Cited by 12 · see citing works

Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids

Dexheimer, T. S., Davoudi, Z., Coussens, N. P., Silvers, T. R., Morris, J., Takebe, N., Said, R., Moscow, J. A., Doroshow, J. H., & Teicher, B. A. (2025) · SLAS DISCOVERY · doi:10.1016/j.slasd.2025.100222 · Cited by 9 · see citing works

Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells

Lee, Y., & Park, D. (2021) · Anticancer Research · doi:10.21873/anticanres.14896 · Cited by 8 · see citing works

RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Davoudi, Z., Dexheimer, T. S., Coussens, N. P., Silvers, T. E., Fox, R. G., Kemp, S. B., Juneja, P., Morris, J., Hollingshead, M. G., Takebe, N., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0582 · Cited by 2 · see citing works

Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer typesPreprint

Davoudi, Z., Dexheimer, T. S., Coussens, N. P., Silvers, T. E., Morris, J., Takebe, N., Doroshow, J. H., & Teicher, B. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.17.623998 · Cited by 1 · see citing works

Rôle de la protéine RICTOR dans le développement des mélanomes

Jebali, A. (2020) · theses.fr (ABES) · doi:10.70675/468ac338zaceaz4caaza391zda7d8da0cb2a

Caractérisation du remodelage de l’organisation du collagène de type I en matrice 3D au cours du vieillissement par micro-imageries optiques : impact sur les propriétés mécaniques et la réponse du mélanome BRAFV600E aux thérapies ciblées

Florent, L. (2024) · doi:10.70675/88568e70z24dfz47bfzba55z457d2e65d84d

A phase I trial of BKM120 combined with vemurafenib in BRAFV600E/k mutant advanced melanoma.

Algazi, A. P., Posch, C., Ortiz‐Urda, S., Cockerill, A., Münster, P. N., & DAUD, A. I. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9101 · Cited by 9 · see citing works

A phase I/II trial of BKM120 combined with vemurafenib (PLX4032) in BRAFV600E/k mutant advanced melanoma.

Kantor, A., DAUD, A. I., Münster, P. N., Ea, R., & Algazi, A. P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.tps8602 · Cited by 5 · see citing works

BKM120 combined with vemurafenib in vemurafenib-refractory BRAF mutant metastatic melanoma: Two cases.

Algazi, A. P., Posch, C., Ortiz‐Urda, S., Cockerill, A., Münster, P. N., & DAUD, A. I. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.e20010 · Cited by 3 · see citing works

Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study

Ribas, A., Gonzalez, R. C., Pavlick, A. C., Hamid, O., Gajewski, T. F., DAUD, A. I., Flaherty, L. E., Logan, T. F., Chmielowski, B., Lewis, K. D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70301-8 · Cited by 300 · see citing works

Vemurafenib in Patients With BRAF V600E Mutation–Positive Advanced Melanoma

Ravnan, M. C., & Matalka, M. S. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.06.009 · Cited by 86 · see citing works